Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates

AI Briefing

• – PBFT02 administration shows promise in reducing brain atrophy and stabilizing plasma NfL levels.
• – No further updates on regulatory or corporate actions.
• – No additional information available.